BOSTON SCIENTIFIC CORP (BSX) is held by 10 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 3 funds opening new positions, 2 funds adding, and 12 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($100.4K bought vs $0 sold). 1 member of Congress reported 5 purchases vs 8 sales. Latest close $43.64 as of Nov 18, 2026.
Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Aug 25, 2026 · Congress to Nov 16, 2026.
Maverick Capital · Mirova US · OrbiMed Advisors — 10 tracked funds hold BSX. See all holders.
Insiders bought on the open market (1 purchase, $100.4K) vs 0 sales ($0). Latest buy: Aug 25, 2026. Insider trading 1 member of Congress reported buying (5 purchases vs 8 sales). Latest buy: Aug 18, 2026. Politician trading
Travere Therapeutics, Inc. (TVTX) · NOVO NORDISK A S (NVO) · Praxis Precision Medicines, Inc. (PRAX) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Abivax S.A. (ABVX) — stocks the same funds also hold. See all related stocks.
| Fund | Portfolio weight | Shares | Change vs prev. quarter |
|---|---|---|---|
| Maverick Capital | 2.24% | 5,937,553 | ADDED (+41.5%) Q3 filed Nov 16 |
| Mirova US | 1.42% | 3,101,478 | ADDED (+40.8%) Q3 filed Nov 5 |
| OrbiMed Advisors | 1.17% | 1,483,200 | TRIMMED (-37.7%) Q3 filed Nov 16 |
| Deerfield Management | 0.59% | 1,315,000 | NEW Q3 filed Nov 16 |
| Causeway Capital Management | 0.33% | 720,339 | NEW Q3 filed Nov 13 |
| Perceptive Advisors | 0.16% | 250,000 | NEW Q3 filed Nov 16 |
| Saturna Capital | 0.01% | 17,835 | TRIMMED (-58.3%) Q3 filed Nov 16 |
| Dodge & Cox Funds | <0.01% | 87,485 | TRIMMED (-1.6%) Q3 filed Nov 13 |
| Mairs & Power Funds | <0.01% | 9,914 | TRIMMED (-2.6%) Q3 filed Nov 16 |
| Polen Capital Management | <0.01% | 4,750 | TRIMMED (-99.2%) Q3 filed Nov 13 |
| Maverick Capital | — | — | EXITED |
| Lone Pine Capital | — | — | EXITED |
| Winslow Capital Management | — | — | EXITED |
| Sands Capital Management | — | — | EXITED |
| Edgewood Management | — | — | EXITED |
| Alphinity Investment Management | — | — | EXITED |
| Atalanta Sosnoff Capital | — | — | EXITED |
Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.
Price change since quarter-end: -0.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.
Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.
Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.
Tracked funds holding this stock, by quarter (2025Q4–2025Q4, 1 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.
| Institutions holding | 1,479 of 8,857 filers |
| Long-only filers among them | 1,472 |
| Change vs 2026 Q1 | -171 net · 1,202 entered · 1,373 exited |
| Shares reported, all filers | 1,316,504,087 |
| Reported value, all filers | $57.1B |
Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).
| Exchange | NYSE |
| Industry | Surgical & Medical Instruments & Apparatus (SIC 3841) |
| Revenue · FY2025 | $20.1B |
| Net income · FY2025 | $2.9B |
| Total assets · FY2025 | $43.7B |
| Shares outstanding | 1,449,229,526 |
| Market cap (at latest close) | $63.2B |
Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 30, 2026.
| Shares short · Oct 15, 2026 | 40,708,019 |
| Share of shares outstanding | 2.81% |
| Days to cover | 2.59 |
Shares short at recent settlements — Jul 31, 2026: 22.3M · Aug 14, 2026: 27.6M · Aug 31, 2026: 48.2M · Sep 15, 2026: 46.5M · Sep 30, 2026: 41.4M · Oct 15, 2026: 40.7M.
Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 30, 2026.
| Shares failed to deliver · Oct 14, 2026 | 0 |
| Share of shares outstanding | 0.00% |
| Fails as a share of short interest · Oct 15, 2026 | 0.0% |
Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.
Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 30, 2026.
1 insider bought on the open market in the last 90 days (1 purchase, $100.4K), against 0 sales by 0 insiders ($0). Latest buy: Aug 25, 2026.
Source: SEC Form 4 filings. Open-market transactions only.
| Latest open-market buy | Transaction price | Price change since disclosure |
|---|---|---|
| Morano Susan E · 2,040 shares on Aug 25, 2026 · filed Aug 26, 2026 | $49.22 | -7.8% (close Aug 27, 2026 → Nov 17, 2026) |
Reference close is the first trading day after the filing (Aug 27, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).
Recent open-market trades
| Date | Insider | Role | Buy / Sell | Shares | Price | Value | Source |
|---|---|---|---|---|---|---|---|
| Aug 25, 2026 | Morano Susan E | Buy | 2,040 | $49.22 | $100.4K | SEC filing |
Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.
| Filed | Seller | Role | Shares to sell | Market value | Approx. sale date | Source |
|---|---|---|---|---|---|---|
| Feb 2, 2026 | MICHAEL F MAHONEY | Officer, Director | 160,901 | $15.0M | Feb 2, 2026 | SEC filing |
| Dec 1, 2025 | ARTHUR C BUTCHER | Officer | 17,313 | $1.8M | Dec 1, 2025 | SEC filing |
| Nov 6, 2025 | Zane Ellen M | Director | 2,901 | $284.2K | Nov 6, 2025 | SEC filing |
| Nov 3, 2025 | JOSEPH M FITZGERALD | Officer | 50,000 | $5.0M | Nov 3, 2025 | SEC filing |
| Oct 28, 2025 | Zane Ellen M | Director | 2,901 | $296.6K | Oct 28, 2025 | SEC filing |
| Oct 27, 2025 | Zane Ellen M | Director | 9,990 | $1.0M | Oct 27, 2025 | SEC filing |
| Oct 1, 2025 | JOSEPH M FITZGERALD | Officer | 50,000 | $4.9M | Oct 1, 2025 | SEC filing |
| Sep 2, 2025 | JOSEPH M FITZGERALD | Officer | 50,000 | $5.3M | Sep 2, 2025 | SEC filing |
| Aug 1, 2025 | ARTHUR C BUTCHER | Officer | 17,313 | $1.8M | Aug 1, 2025 | SEC filing |
| Aug 1, 2025 | JOSEPH M FITZGERALD | Officer | 50,000 | $5.2M | Aug 1, 2025 | SEC filing |
A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.
| Filed | Filer | Form | Shares | % owned | Event date | Source |
|---|---|---|---|---|---|---|
| Aug 6, 2026 | FMR LLC | SC 13G/A | 46,378,258.61 | 3.1% | Jun 30, 2026 | SEC filing |
| May 6, 2026 | FMR LLC | SC 13G/A | 75,835,683.3 | 5.1% | Mar 31, 2026 | SEC filing |
| Apr 29, 2026 | Vanguard Capital Management | SC 13G | 111,127,205 | 7.5% | Mar 31, 2026 | SEC filing |
| Mar 26, 2026 | The Vanguard Group | SC 13G/A | 0 | 0.0% | Mar 13, 2026 | SEC filing |
| Aug 6, 2025 | FMR LLC | SC 13G/A | 110,320,937.81 | 7.5% | Jun 30, 2025 | SEC filing |
| Apr 17, 2025 | BlackRock, Inc. | SC 13G/A | 113,006,671 | 7.6% | Mar 31, 2025 | SEC filing |
| Apr 7, 2025 | FMR LLC | SC 13G/A | 141,149,781.51 | 9.6% | Dec 29, 2023 | SEC filing |
One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.
1 member of Congress reported buying (5 purchases vs 8 sales). Bought by Democrats. Latest buy: Aug 18, 2026.
Source: U.S. House Clerk and U.S. Senate eFD STOCK Act periodic transaction reports, as of Nov 16, 2026. Reported amounts are ranges, and reports can arrive up to 45 days after the trade.
Recent activity by member
| Member | Chamber | Party | Buys | Sells | Latest | Amount range |
|---|---|---|---|---|---|---|
| Hern, Kevin | House | R | 0 | 6 | Sep 9, 2026 | $50,001 - $100,000 |
| Cisneros, Gilbert | House | D | 5 | 1 | Aug 18, 2026 | $1,001 - $15,000 |
| Boozman, John | Senate | R | 0 | 1 | Jun 4, 2026 | $1,001 - 15,000 |
Member-level activity in the current window, most recent first (House data to Nov 16, 2026, Senate to Oct 1, 2026). House reports arrive as PDFs without transaction-level rows in the current corpus, so this table shows per-member totals, not individual trades; the member page lists the underlying filings. Senate rows link the same way — the member page carries the eFD filing links.
Industry: Surgical & Medical Instruments & Apparatus (SIC 3841). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.
None of the members who traded this stock in the current window sit on these committees.
Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.
Lobbying: 365 Lobbying Disclosure Act filings named this company as client, 1999–2026; most common issues: Health Issues (229), Taxation/Internal Revenue Code (169), Medicare/Medicaid (123).
Federal contracts: $162.4M in obligated amounts, fiscal years 2021–2026.
| Fiscal year | Obligated amount |
|---|---|
| FY2021 | $27.6M |
| FY2022 | $27.3M |
| FY2023 | $32.1M |
| FY2024 | $23.6M |
| FY2025 | $30.0M |
| FY2026 | $21.7M |
Largest awards collected
| Award ID | Agency | Amount | Start |
|---|---|---|---|
| FA442719CA020 | Department of Defense | $4.7M | Sep 1, 2019 |
| 36C25722P0417 | Department of Veterans Affairs | $4.0M | Apr 23, 2022 |
| 36C25623P0027 | Department of Veterans Affairs | $3.8M | Oct 1, 2022 |
| 36C24823K0018 | Department of Veterans Affairs | $1.7M | Jan 1, 2022 |
| 36C24123P1146 | Department of Veterans Affairs | $1.6M | Sep 30, 2023 |
Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.
Insiders
· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions
· Opportunistic Buys (Non-Routine) — Last 90 days: 2 or more insiders with no routine buying pattern bought on the open market
Politicians
· Bought by Members — Last 6 months: bought by a member of the U.S. Congress
Financial Screens
· Graham — Sound finances and a long run of profits
· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%
· Earnings Quality (Cash Conversion) — Profits that actually come back as cash
Key figures
· Graham — Current ratio: 1.62 · Straight profitable years: 5 · Debt ratio: — · Latest net income: $2.9B
· Cash Flow (FCF) — Latest FCF: $3.7B · FCF yield: 5.7% · Positive FCF years: 3
· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 1.67 · Operating cash flow: $4.5B · Net income: $2.9B
· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $100.4K · Latest buy: Aug 25, 2026
· Opportunistic Buys (Non-Routine) — Opportunistic buyers: 4 · Buy txns: 6 · Buy value: $9.5M · Latest buy: Aug 25, 2026
· Bought by Members — Members buying: 1 · Buy txns: 5 · Sell txns: 8 · Latest buy: Aug 18, 2026
Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.
· Super-investor 13F BEST — appeared in 1 of the last 40 quarterly lists; latest 2025 Q4, ranked #42 of 50.
· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2026 Q2, ranked #47 of 50.
· Politician BEST — appeared in 3 of the last 20 quarterly lists; latest 2026 Q2, ranked #36 of 50.
| 13F signal (2021 Q3 – 2026 Q1) | Events | Win rate | Avg return | SPY | Excess |
|---|---|---|---|---|---|
| Heavy accumulation — 3+ tracked funds increased together | 3 | 33.3% | -1.1% | +3.3% | -4.4% |
| Share count tripled (3x) | 1 | 0.0% | -25.0% | +2.9% | -27.9% |
Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.
Also held by the tracked funds that hold BSX — ranked by lift, the co-holding pattern described in Methodology: Travere Therapeutics, Inc. (TVTX) · NOVO NORDISK A S (NVO) · Praxis Precision Medicines, Inc. (PRAX) · BIOCRYST PHARMACEUTICALS INC (BCRX) · Abivax S.A. (ABVX) · ALNYLAM PHARMACEUTICALS, INC. (ALNY) · BIOGEN INC. (BIIB) · BELITE BIO, INC (BLTE).
| Filed | Items | Source |
|---|---|---|
| Nov 17, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 28, 2026 | 2.02 Results of Operations and Financial Condition · 9.01 Financial Statements and Exhibits | SEC filing |
| Oct 7, 2026 | 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 8.01 Other Events · 9.01 Financial Statements and Exhibits | SEC filing |
Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.
Travere Therapeutics, Inc. (TVTX) · Track Record: how the signals scored · Practice timing on BSX
One email a week: the week’s new filings and research. Subscribe free
Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.